The European Medicines Agency is to introduce certain procedural changes to ensure there is “to the greatest extent possible” separation between the experts it uses to offer companies scientific advice about a drug and the experts who are subsequently involved in reviewing the same medicine.
The changes, which are likely to be introduced in the first quarter of 2020, are in response to an inquiry by the European Ombudsman, Emily O'Reilly